<DOC>
	<DOCNO>NCT00967018</DOCNO>
	<brief_summary>Patients complete trial ; CS27 ( NCT00738673 ) , CS28 ( NCT00831233 ) , CS30 ( NCT00833248 ) CS31 ( NCT00884273 ) give opportunity receive monthly dos degarelix drug launch country . Safety parameter electrocardiogram ( ECG ) , blood urine sample general health state study . Note : patient complete CS27 trial participate CS34 trial .</brief_summary>
	<brief_title>A Long Term Safety Study Degarelix Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Completed trial ; FE 200486 CS27 , CS28 , CS30 CS31 Discontinued trial : FE 200486 CS27 , CS28 , CS30 CS31</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Safety parameter</keyword>
	<keyword>ECG , blood urine sample</keyword>
	<keyword>general health state</keyword>
</DOC>